Key Insights

Highlights

Success Rate

83% trial completion

Published Results

21 trials with published results (35%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

13.3%

8 terminated out of 60 trials

Success Rate

82.6%

-3.9% vs benchmark

Late-Stage Pipeline

42%

25 trials in Phase 3/4

Results Transparency

55%

21 of 38 completed with results

Key Signals

21 with results83% success

Data Visualizations

Phase Distribution

35Total
Not Applicable (7)
P 2 (3)
P 3 (14)
P 4 (11)

Trial Status

Completed38
Terminated8
Unknown5
Recruiting3
Withdrawn3
Active Not Recruiting2

Trial Success Rate

82.6%

Benchmark: 86.5%

Based on 38 completed trials

Clinical Trials (60)

Showing 20 of 20 trials
NCT01422694Recruiting

Natural History and Development of Spondyloarthritis

NCT06842316Recruiting

Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases

NCT05879419Phase 4Active Not Recruiting

Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases

NCT06998316Not Yet Recruiting

Spondylo-arthritis Screening Tool Among Patient Suffering From Inflammatory Bowel Disease

NCT04341233WithdrawnPrimary

Enhanced Clinics for Patients Diagnosed With Ankylosing Spondylitis and Psoriatic Arthritis

NCT03733925Phase 4CompletedPrimary

A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis

NCT04301128Not ApplicableCompleted

The Effect of Mobile Application on Subcutaneous Anti-TNF Drug Administration:Ankylosing Spondylitis Patients

NCT05961267Completed

Study of Gynecological Follow-up of Patients With Autoimmune Disease or Inflammatory Rheumatism

NCT04731831Recruiting

Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response.

NCT01208207Phase 3CompletedPrimary

A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)

NCT04947579Phase 2TerminatedPrimary

A Study of CC-99677 in Participants With Active Ankylosing Spondylitis

NCT05647577Active Not Recruiting

The Relationship Between Inflammatory ARTritis and CArdiac DIseAse

NCT02183168Phase 3CompletedPrimary

Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis

NCT03662919Completed

One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study

NCT04810715Completed

Frequency of Pes Planus and Posterior Tibial Tendon Dysfunction in Patients With Ankylosing Spondylitis

NCT03778515TerminatedPrimary

Novel Quantitative MRI for Axial Spondyloarthritis

NCT05283096Unknown

Survey About Diet in Chronic Inflammatory Rheumatic Diseases

NCT03033095Not ApplicableCompletedPrimary

Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis by Combinatorial Analysis of Serum Biomarkers

NCT03880968CompletedPrimary

Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis

NCT03561649Not ApplicableCompletedPrimary

Prediction of Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive SpA

Scroll to load more

Research Network

Activity Timeline